Theravance’s Telavancin NDA Could Get FDA Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Antibiotics for skin-structure infections could face new FDA hurdles.
You may also be interested in...
Cubist’s First-Quarter Rise Divides Analysts
With at least five rivals on the near horizon, some see Cubist’s cup as half-full, others as half-empty.
Cubist’s First-Quarter Rise Divides Analysts
With at least five rivals on the near horizon, some see Cubist’s cup as half-full, others as half-empty.
FDA Anti-Infective Drugs Advisory Committee To Review Two Antibiotics
Johnson & Johnson’s ceftobiprole and Theravance’s telavancin will be discussed Feb. 27-28.